Medical Developments International Limited · ASX:MVP

Medical Developments International — Investor Presentation (April 2004)

11 slides from Medical Developments International's investor presentation, Apr 29, 2004

  1. Slide 1: Medical Developments International Limited Presentation

    Medical Developments International Limited (“MDI’’) Presentation Sydney — 29 April 2004

  2. Slide 2: Introduction — Pharmaceutical Business

    Introduction — Pharmaceutical Business Single Product - Analgesic for emergency pain relief (Penthrox Inhaler) =» Only manufacturer worldwide = Drug is TGA and Medsafe (NZ) approved = Plant is GMP Certified =» 48% of MDI sales =» Current Customers: + Australian Ambulance Services * Australian Defenc

  3. Slide 3: Introduction — Medical Equipment

    Introduction — Medical Equipment Medical Equipment =» Key Products Space Chambers (22% of sales) Face masks (8% of sales) Peak Flow meters (4% of sales) * Oxygen Equipment (4% of sales) = 30 devices registered with the TGA * Space Chambers and Peak Flow Meters have CE Marks and registered in USA and

  4. Slide 4: Introduction — Veterinary Equipment Business

    © = & a G se Aven G 2 GS iD cL & G = oy ° @ ea © Oo w 2 oS @ = Introduction — Veterinary Equipment Business Veterinary Equipment =» Key Products « Anaesthetic machines Biopsy punches = 8% of sales = 66% of revenue from exports

  5. Slide 5: Growth Strategy — Medical Devices

    © = 2 a © = G 2 & iD cL & G = oy 2 @ ea © Oo w 2 oS @ = Growth Strategy — Medical Devices Grow internationally and selectively introduce new but related products Products New Current Medical Devices New Product #1 New Product #2 Product upgrade in Vet market Anaesthesia Machines Spacers PFM ee (nter

  6. Slide 6: Drive growth in current markets

    Growth Strategy — Penthrox Inhaler Drive growth in current markets Methoxyflurane Growth Strategy © Ze 2 fon AS & 2 Zz New D n i= rd o > E 3 Q. c 2 S & =| Rescue Services (Australia) a 2 % y Military (Australia) & < 3 Current Ambulance (Australia) = Research Institutions Current New Markets (Custome

  7. Slide 7: Expand into similar markets internationally

    Growth Strategy — Penthrox Inhaler Expand into similar markets internationally Methoxyflurane Growth Strategy New Rescue Services (Australia) Early Priorities Military (Australia) USA Current Ambulance (Australia) ==> Middle East New Zealand South Africa Applications/Uses © = 2 a © = G 2 & iD cL & G

  8. Slide 8: Our registration strategy is evolving

    Growth Strategy — Penthrox Inhaler Our registration strategy is evolving Pending Applications Country Target Registration Date UAE FY05 USA FY06 Saudi Arabia FY06 South Africa FY06 Applications Under Consideration © = 2 a G = G 2 & iD cL & G = oy 2 @ ea © Oo w 2 oS @ = Canada South Korea UK Thailand

  9. Slide 9: Expand the uses of the Penthrox Inhaler

    Growth Strategy — Penthrox Inhaler Expand the uses of the Penthrox Inhaler Methoxyflurane Growth Strategy Hospitals New GPs/Specialists Mass Disaster/Emergency Relief Rescue Services (Australia) Military (Australia) Applications/Uses Current Ambulance (Australia) © = 2 a © = G 2 & iD cL & G = oy 2 @

  10. Slide 10: There is considerable scope for much wider use of the Penthrox Inhaler

    Growth Strategy — Penthrox Inhaler There is considerable scope for much wider use of the Penthrox Inhaler Potential “New” Uses of the Penthrox Inhaler * Emergency Wards + In-patient Wards * Obstetrics/Gynaecology * Post-operative Wards * GP Rooms * Dentistry « Plastic Surgery Rooms © = 2 a G = G 2 &

  11. Slide 11: Projected Financial Performance

    Projected Financial Performance FY05 will be a high growth year. FY06 should be even better FY2004 Meet or exceed MDA proforma earnings pro-rata for FY2003 (per Prospectus) FY2005 Revenue of at least $8.2m (50% growth over FY2003) = Penthrox Inhaler . Organic growth in Oz Ambulance . Research labora

Medical Developments International — Investor Presentation (April 2004) on 6ix